Science & Enterprise subscription

Follow us on Twitter

  • Results from a large-scale clinical trial show almost the same health outcomes for patients prescribed high or low… https://t.co/cAg7Ygkv3I
    about 19 hours ago
  • New post on Science and Enterprise: Trial Shows Same High/Low Dose Aspirin Outcomes https://t.co/N8mjm3cWX8 #Science #Business
    about 19 hours ago
  • Venture funding for start-ups providing artificial intelligence services in health care climbed to a record high vo… https://t.co/FHzRPWsgKR
    about 3 days ago
  • New post on Science and Enterprise: Infographic – Health Care A.I. Funds Jump in Q1 https://t.co/4L1DrqPRFT #Science #Business
    about 3 days ago
  • This New York Times essay got here just in time ... Your Car, Toaster, Even Washing Machine, Can’t Work Without The… https://t.co/cuRLpV3PIT
    about 3 days ago

Please share Science & Enterprise

Moderna Supplying 500M Vaccine Doses to Covax

Vaccine delivery to Philippines

Moderna Inc. is providing up to 500 million doses of its Covid-19 vaccine to the Covax Facility, an international project distributing vaccines to low-income countries. . . . → Read More: Moderna Supplying 500M Vaccine Doses to Covax

Moderna Developing Flu, HIV, Nipah Vaccines

Syringe and three vials

Moderna Inc., developer of a currently authorized Covid-19 vaccine, is expanding its vaccine pipeline to cover three more common infectious viral diseases. . . . → Read More: Moderna Developing Flu, HIV, Nipah Vaccines

Moderna Gains $483M for Covid-19 Vaccine

SARS-Cov-2 virus

A government preparedness agency awarded biotechnology company Moderna Inc. $483 million to advance its Covid-19 vaccine through clinical trials. . . . → Read More: Moderna Gains $483M for Covid-19 Vaccine

Moderna Funding University Immunology Research

Immune - scrabble tiles

A biotechnology enterprise is financing a collaboration with Harvard Medical School that aims to discover new mechanisms for treating immune system disorders. . . . → Read More: Moderna Funding University Immunology Research

Moderna, Merck Partner on Personal Cancer Vaccines

Scanning electron micrograph of a human T-cell lymphocyte (National Institute of Allergy and Infectious Diseases, NIH)

29 June 2016. Biotechnology company Moderna Therapeutics and drug maker Merck are developing therapeutic vaccines using messenger RNA that address unique genetic patterns in patients’ tumors. The deal is expected to bring Moderna an immediate payment of . . . → Read More: Moderna, Merck Partner on Personal Cancer Vaccines

Infographic – Public Money Funds Covid-19 Vaccines

Chart: Covid-19 vaccine funding

As the race to produce and distribute Covid-19 vaccines intensifies, financing of this global public health project is starting to emerge. . . . → Read More: Infographic – Public Money Funds Covid-19 Vaccines

Novavax Joins Alternative Second Shot Vaccine Trial

Syringes

Vaccine developer Novavax is taking part in a clinical trial testing effects of different Covid-19 vaccines in first and second immunizations. . . . → Read More: Novavax Joins Alternative Second Shot Vaccine Trial

Vaccine Stops Lyme Bacteria in Preclinical Test

Adult deer tick

A study with lab mice shows an experimental vaccine with engineered bacteria produces antibodies and protects against microbes causing Lyme disease. . . . → Read More: Vaccine Stops Lyme Bacteria in Preclinical Test

NIH Trial Testing mRNA Vaccine Allergic Effects

Syringe

A clinical trial is underway testing for allergic reactions to Covid-19 vaccines using messenger RNA for invoking an immune response. . . . → Read More: NIH Trial Testing mRNA Vaccine Allergic Effects

Infographic – Steady Growth for mRNA Trials

Messenger RNA clinical trials

The pandemic has demonstrated messenger RNA’s recognized potential for vaccines and treatments that induce an immune response. . . . → Read More: Infographic – Steady Growth for mRNA Trials